ibh-symbol
Behavioral HealthHealth AnalyticsPostersPublicationsSubstance Abuse

Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system

Jared Beaumont, M.P.H.1, Theresa Cassidy, M.P.H.1, Taryn Dailey Govoni, M.P.H.1

Presented at International Conference on Opioids 2017

See our poster for “Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system” here

Abstract

Post-market surveillance data indicate low abuse levels of tapentadol products,
but research regarding the route of administration profile of tapentadol abusers is
limited. Our analyses evaluated abuse and routes of administration of tapentadol
within a sample of 270,695 adults assessed for substance abuse problems during
January 2012 through September 2016.

See our poster for “Abuse and route of administration prevalence for tapentadol products within the NAVIPPRO® ASI-MV® surveillance system” here